Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparative Effects of Autogenic Inhibition vs Reciprocal Inhibition in Patients With Lower Cross Syndrome

18 settembre 2026 aggiornato da: Foundation University Islamabad

This randomized controlled trial aims to compare the effectiveness of Autogenic Inhibition Muscle Energy Technique (MET) and Reciprocal Inhibition MET in individuals with Lower Crossed Syndrome. Participants will be randomly assigned to two intervention groups. One group will receive Autogenic Inhibition MET, while the other will receive Reciprocal Inhibition MET for the iliopsoas, rectus femoris, and erector spinae muscles. Both groups will also perform the same standardized strengthening exercises targeting the transversus abdominis, gluteus maximus, and gluteus medius muscles to improve muscle balance and functional outcomes.

Panoramica dello studio

Descrizione dettagliata

Participants who meet the eligibility criteria and provide informed consent will be randomly allocated into two experimental groups using a randomization method. The intervention will be carried out over a period of six weeks, with three treatment sessions per week, making a total of 18 sessions for each participant. Before the commencement of each treatment session, all participants will receive a 10-minute hot pack application over the lumbar region to promote muscle relaxation, reduce soft tissue stiffness, and prepare the muscles for manual therapy. Following the hot pack, participants will receive the assigned Muscle Energy Technique (MET) according to their respective group.

Participants in Experimental Group 1 will receive Autogenic Inhibition Muscle Energy Technique (Modified Post-Facilitation Stretch Protocol) targeting the iliopsoas, rectus femoris, and erector spinae muscles. The therapist will position the involved muscle at its initial barrier, after which the participant will perform an isometric contraction of approximately 20-30% of maximal effort for 7-10 seconds against the therapist's resistance. After relaxation, the muscle will be gently stretched to the new barrier and the stretch will be maintained for 30 seconds. This procedure will be repeated 3-5 times for each muscle during every treatment session.

Participants in Experimental Group 2 will receive Reciprocal Inhibition Muscle Energy Technique for the same muscle groups. The therapist will position the muscle at the initial barrier, and the participant will perform an isometric contraction of the antagonist muscle using approximately 20-30% of maximal effort for 7-10 seconds. Following relaxation, the therapist will move the muscle to the new barrier and maintain the stretch for 30 seconds. The technique will also be repeated 3-5 times for each targeted muscle during every treatment session.

Both groups will follow an identical strengthening exercise program to address the weak muscles commonly associated with Lower Crossed Syndrome. The strengthening program will target the transversus abdominis, gluteus maximus, and gluteus medius muscles using progressive therapeutic exercises prescribed according to the participant's tolerance. During the first two weeks, the intervention will primarily emphasize improving flexibility and reducing muscle tightness through the assigned MET. From Week 3 to Week 6, participants will continue receiving their allocated MET while simultaneously performing the strengthening exercises to restore muscle balance, improve lumbopelvic stability, and enhance functional performance. Exercise intensity and repetitions will be progressed gradually throughout the intervention while maintaining proper technique and patient comfort.

The treatment duration, session frequency, hot pack application, strengthening protocol, therapist supervision, and progression of exercises will remain identical for both groups. The only difference between the two groups will be the type of Muscle Energy Technique employed-Autogenic Inhibition MET in Experimental Group 1 and Reciprocal Inhibition MET in Experimental Group 2. Outcome measures will be recorded before and after completion of the intervention period to evaluate the comparative effectiveness of both treatment approaches in improving pain, muscle flexibility, lumbar range of motion, posture, and functional disability among individuals with Lower Crossed Syndrome.

Tipo di studio

Interventistico

Iscrizione (Stimato)

46

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Punjab Province
      • Islamabad, Punjab Province, Pakistan, 44000
        • Reclutamento
        • Foundation University College of Physical Therapy
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 19 anni a 35 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria

  • Age 19-35 years.
  • Both genders will include in this study.
  • According to Janda's Approach, Clinical diagnosis of LCS based on ≥3 positive clinical tests.
  • Patient with positive modified Thomas test, Patients with a positive testing of prone hip extension test, Patients with a positive test of trunk flexion test, Patients with tight erector spinae muscles.
  • Participants with no lumbar pain to moderate lumbar pain (NPRS0-6) will be included.
  • Painless movement and activity.
  • Pain only produced by sustained loading in relevant position, which is then relieved after maintaining a corrected posture for 5 minutes, indicating posture-related pain.

Exclusion Criteria

  • Leg symptoms when walking, eased in flexion (Signs of stenosis)
  • Pain due to repetitive movement
  • Lumbar Radiculopathy
  • Neurological Symptoms (Paresthesia/numbness)
  • Structural deformity (Kyphosis, lordosis, scoliosis, spondylosis, spondylolysis, spondylolisthesis)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Autogenic Inhibtion (Group A)

Group A will receive Autogenic inhibition using PFS, preceded by 10 minutes heating pad application. 30% Isometric contraction(7-10 sec), followed by relaxation & 30 sec stretch, will be repeated 3-5 time. From Weeks 3-6, strenghtening exercises for hip extensors & Transverse Abdominis will be performed.

Experimental Group 1 will receive MET based on autogenic inhibition using Modified Post-Facilitation Stretch (PFS) for the iliopsoas, rectus femoris, and erector spinae. For the iliopsoas, subjects will assume modified Thomas position and perform a 30% isometric contraction for 7-10 seconds, followed by relaxation and hip extension stretching for 30 seconds. For rectus femoris, the procedure will be performed in modified Thomas position with knee flexion, followed by hip extension and knee flexion stretching for 30 seconds. For erector spinae, subjects will sit with legs hanging and arms crossed, perform a 30% isometric contraction for 7-10 seconds, followed by trunk flexion for 30 seconds. Each technique will include 30-second rest and 3-5 repetitions. From the 3rd to 6th week, strengthening will include TA activation, gluteus maximus bridging, and gluteus medius abduction.

Sperimentale: Reciprocal Inhibition (Group B)

Group B will receive Reciprocal Inhibition using using MET,preceding by a 10 minute heating pad application. A 30% isometric contraction(7-10 sec) of antagonist muscle, followed by relaxation & 30-60sec passive stretch, will be repeated 3-5 times. From 3-6 weeks strenghening exercises for hip extensor & transverse abdominis will be performed.

Experimental Group 2 will receive MET based on reciprocal inhibition for the iliopsoas, rectus femoris, and erector spinae. For the iliopsoas, subjects will assume modified Thomas position and perform a 30% isometric contraction of the gluteus maximus for 7-10 seconds, followed by relaxation and passive hip extension stretching for 30-60 seconds. For rectus femoris, subjects will assume modified Thomas position followed by a 30% isometric hamstring contraction for 7-10 seconds and passive stretching into hip extension with knee flexion for 30-60 seconds. For Erector Spinae, subjects will sit with legs hanging and perform a 30% isometric transverse abdominis contraction for 7-10 seconds, followed by trunk flexion for 30-60 seconds. From the 3rd to 6th week, strengthening will include TA activation, gluteus maximus bridging, and gluteus medius abduction.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Lumbar Extensor Muscle Length
Lasso di tempo: Baseline & after 6 weeks of intervention.

The Modified Schober's Test will be used to assess lumbar extensor muscle length and lumbar spine mobility. The increase in distance between standardized spinal landmarks during maximal forward flexion will be measured and recorded in centimeters (cm). A greater increase in distance indicates greater lumbar extensor flexibility or length.

Baseline & after 6 weeks of intervention.
Functional Movement dysfunction
Lasso di tempo: Baseline and after 6 Weeks of intervention.

Functional Movement Screen will be used to assess functional movement dysfunction. It consists of seven tests, scored on a 0-3 scale, with a total score ranging from 0 to 21. Lower scores indicate greater movement dysfunction.

Baseline and after 6 Weeks of intervention.
Back Pain
Lasso di tempo: Baseline and after 6 Weeks of intervention.

Pain intensity will be assessed using the Numerical Pain Rating Scale, ranging from 0 (no pain) to 10 (worst possible pain). Participants reporting pain intensity scores of 0-6 on the NPRS will be eligible for inclusion in the study.

Baseline and after 6 Weeks of intervention.
Functional Disability
Lasso di tempo: Baseline and after 6 Weeks of intervention

Functional disability will be assessed using the Oswestry Disability Index (ODI), a 10-item questionnaire, with each item consisting of six response options.

Baseline and after 6 Weeks of intervention
Lumbar Range Of Motion
Lasso di tempo: Baseline and after 6 Weeks of invention

Lumbar spine range of motion (ROM) will be assessed using inclinometer, including lumbar flexion, extension, and lateral flexion. Lumbar ROM will be determined by measuring the difference between the readings obtained at the T12 and S2 spinal landmarks.

Baseline and after 6 Weeks of invention

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 febbraio 2026

Completamento primario (Stimato)

18 dicembre 2026

Completamento dello studio (Stimato)

18 gennaio 2027

Date di iscrizione allo studio

Primo inviato

18 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

18 settembre 2026

Primo Inserito (Effettivo)

24 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • FUI/FUCP/CTR/MSMSK/MomnaKhadim

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi